Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression

Seminars in Cancer Biology

Volumn 35, Issue , 2015, Pages 3-10

  Giussani, Marta ^a   Merlino, Giuseppe ^a   Cappelletti, Vera ^a   Tagliabue, Elda ^a   Daidone, Maria Grazia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; ECM related signatures; Extracellular matrix; Tumor microenvironment; Tumor stroma component

Indexed keywords

BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; EXTRACELLULAR MATRIX; GENETIC ASSOCIATION; HUMAN; INTRADUCTAL CARCINOMA; MOLECULAR PATHOLOGY; NONHUMAN; REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; BREAST NEOPLASMS; CARCINOMA IN SITU; CELL COMMUNICATION; DISEASE COURSE; FEMALE; GENETICS; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR INVASION; TUMOR RECURRENCE;

BIOLOGICAL MARKER;

ANIMALS; BIOMARKERS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CELL COMMUNICATION; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84948680447     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.09.012     Document Type: Review

References (85)

1. Egeblad M., Nakasone E.S., Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 2010, 18:884-901.
2. Marusyk A., Tabassum D.P., Altrock P.M., Almendro V., Michor F., Polyak K. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 2014, 514:54-58.
3. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406. %20.
4. Pickup M.W., Mouw J.K., Weaver V.M. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014, 15:1243-1253.
5. Pupa S.M., Ménard S., Forti S., Tagliabue E. New insights into the role of extracellular matrix during tumor onset and progression. J. Cell. Physiol. 2002, 192:259-267.
6. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
7. Singer C.F., Gschwantler-Kaulich D., Fink-Retter A., Haas C., Hudelist G., Czerwenka K., et al. Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res. Treat. 2008, 110:273-281.
8. Finak G., Sadekova S., Pepin F., Hallett M., Meterissian S., Halwani F., et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res. 2006, 8:R58.
9. Turashvili G., Bouchal J., Baumforth K., Wei W., Dziechciarkova M., Ehrmann J., et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007, 7:55.
10. Ma X.J., Dahiya S., Richardson E., Erlander M., Sgroi D.C. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009, 11:R7.
11. Chou J., Shahi P., Werb Z. microRNA-mediated regulation of the tumor microenvironment. Cell Cycle 2013, 12:3262-3271.
12. Piccinini A.M., Midwood K.S. Illustrating the interplay between the extracellular matrix and microRNAs. Int. J. Exp. Pathol. 2014, 95:158-180.
13. Wapnir I.L., Dignam J.J., Fisher B., Mamounas E.P., Anderson S.J., Julian T.B., et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J. Natl. Cancer Inst. 2011, 103:478-488.
14. Bijker N., Meijnen P., Peterse J.L., Bogaerts J., Van H.I., Julien J.P., et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J. Clin. Oncol. 2006, 24:3381-3387. %20.
15. Cuzick J., Sestak I., Pinder S.E., Ellis I.O., Forsyth S., Bundred N.J., et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011, 12:21-29.
16. Lopez-Garcia M.A., Geyer F.C., Lacroix-Triki M., Marchio C., Reis-Filho J.S. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 2010, 57:171-192.
17. Cowell C.F., Weigelt B., Sakr R.A., Ng C.K., Hicks J., King T.A., et al. Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol. Oncol. 2013, 7:859-869.
18. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
19. Vincent-Salomon A., Lucchesi C., Gruel N., Raynal V., Pierron G., Goudefroye R., et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin. Cancer Res. 2008, 14:1956-1965.
20. Hernandez L., Wilkerson P.M., Lambros M.B., Campion-Flora A., Rodrigues D.N., Gauthier A., et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J. Pathol. 2012, 227:42-52.
21. Heselmeyer-Haddad K., Berroa Garcia L.Y., Bradley A., Ortiz-Melendez C., Lee W.J., Christensen R., et al. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. Am. J. Pathol. 2012, 181:1807-1822.
22. Vargas A.C., Cart Reed A.E., Waddell N., Lane A., Reid L.E., Smart C.E., et al. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression. Breast Cancer Res. Treat. 2012, 135:153-165.
23. Lee S., Stewart S., Nagtegaal I., Luo J., Wu Y., Colditz G., et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res. 2012, 72:4574-4586.
24. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat. Rev. Cancer 2006, 6:281-291.
25. Janerich D.T., Hoff M.B. Evidence for a crossover in breast cancer risk factors. Am. J. Epidemiol. 1982, 116:737-742.
26. Lyons T.R., O'Brien J., Borges V.F., Conklin M.W., Keely P.J., Eliceiri K.W., et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat. Med. 2011, 17:1109-1115.
27. Barker H.E., Chang J., Cox T.R., Lang G., Bird D., Nicolau M., et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res. 2011, 71:1561-1572.
28. Barsky S.H., Karlin N.J. Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression. J. Mammary Gland Biol. Neoplasia 2005, 10:249-260.
29. Hu M., Yao J., Carroll D.K., Weremowicz S., Chen H., Carrasco D., et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008, 13:394-406.
30. Curigliano G., Disalvatore D., Esposito A., Pruneri G., Lazzeroni M., Guerrieri-Gonzaga A., et al. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Ann. Oncol. 2015, 26:682-687.
31. Generali D., Buffa F.M., Deb S., Cummings M., Reid L.E., Taylor M., et al. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. Br. J. Cancer 2014, 111:46-54.
32. Assi V., Warwick J., Cuzick J., Duffy S.W. Clinical and epidemiological issues in mammographic density. Nat. Rev. Clin. Oncol. 2011, 9:33-40.
33. Chang H.Y., Sneddon J.B., Alizadeh A.A., Sood R., West R.B., Montgomery K., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004, 2:E7.
34. Chang H.Y., Nuyten D.S., Sneddon J.B., Hastie T., Tibshirani R., Sorlie T., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:3738-3743.
35. Van de Vijver M.J., He Y.D., Van'TVeer L.J., Dai H., Hart A.A., Voskuil D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002, 347:1999-2009.
36. West R.B., Nuyten D.S., Subramanian S., Nielsen T.O., Corless C.L., Rubin B.P., et al. Determination of stromal signatures in breast carcinoma. PLoS Biol. 2005, 3:e187.
37. Beck A.H., Espinosa I., Gilks C.B., van de R.M., West R.B. The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab. Invest. 2008, 88:591-601.
38. Chen J.L., Espinosa I., Lin A.Y., Liao O.Y., van de R.M., West R.B. Stromal responses among common carcinomas correlated with clinicopathologic features. Clin. Cancer Res. 2013, 19:5127-5135.
39. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 2006, 98:262-272.
40. Bergamaschi A., Tagliabue E., Sorlie T., Naume B., Triulzi T., Orlandi R., et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol. 2008, 214:357-367.
41. Triulzi T., Casalini P., Sandri M., Ratti F., Carcangiu M.L., Colombo M.P., et al. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS ONE 2013, 8:e56761. 10.1371/journal.pone.0056761.
42. Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 2007, 13:3207-3214.
43. Helleman J., Jansen M.P., Ruigrok-Ritstier K., van S I., Look M.P., Meijer-van Gelder M.E., et al. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin. Cancer Res. 2008, 14:5555-5564.
44. Planche A., Bacac M., Provero P., Fusco C., Delorenzi M., Stehle J.C., et al. Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer. PLoS ONE 2011, 6:e18640.
45. Maurer P., Hohenadl C., Hohenester E., Gohring W., Timpl R., Engel J. The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domain that binds calcium and collagen IV. J. Mol. Biol. 1995, 253:347-357. %20.
46. Raines E.W., Lane T.F., Iruela-Arispe M.L., Ross R., Sage E.H. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:1281-1285.
47. Arnold S.A., Brekken R.A. SPARC: a matricellular regulator of tumorigenesis. J. Cell Commun. Signal. 2009, 3:255-273.
48. Bradshaw A.D., Francki A., Motamed K., Howe C., Sage E.H. Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Mol. Biol. Cell 1999, 10:1569-1579.
49. Chiodoni C., Colombo M.P., Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev. 2010, 29:295-307.
50. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
51. Azim H.A., Singhal S., Ignatiadis M., Desmedt C., Fumagalli D., Veys I., et al. Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis. PLoS ONE 2013, 8:e62451.
52. Dittmer J., Leyh B. The impact of tumor stroma on drug response in breast cancer. Semin. Cancer Biol. 2015, 31:3-15.
53. Jansen M.P., Foekens J.A., van Staveren I.L., Dirkzwager-Kiel M.M., Ritstier K., Look M.P., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Oncol. 2005, 23:732-740.
54. Tavazoie S.F., Alarcon C., Oskarsson T., Padua D., Wang Q., Bos P.D., et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
55. Augoff K., Das M., Bialkowska K., McCue B., Plow E.F., Sossey-Alaoui K. miR-31 is a broad regulator of beta1-integrin expression and function in cancer cells. Mol. Cancer Res. 2011, 9:1500-1508.
56. Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Becette V., et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 2009, 15:68-74.
57. Hess K.R., Anderson K., Symmans W.F., Valero V., Ibrahim N., Mejia J.A., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 2006, 24:4236-4244.
58. Oskarsson T. Extracellular matrix components in breast cancer progression and metastasis. Breast 2013, 22(Suppl 2):S66-S72. 10.1016/j.breast.2013.07.012.:S66-S72.
59. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91:1071-1121.
60. Pang H., Cai L., Yang Y., Chen X., Sui G., Zhao C. Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. Cancer Biother. Radiopharm. 2011, 26:165-173.
61. Yang L., Wei L., Zhao W., Wang X., Zheng G., Zheng M., et al. Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells. Mol. Med. Rep. 2012, 5:373-376.
62. Hattar R., Maller O., McDaniel S., Hansen K.C., Hedman K.J., Lyons T.R., et al. Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes. Breast Cancer Res. 2009, 11:R5.
63. Weigelt B., Lo A.T., Park C.C., Gray J.W., Bissell M.J. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res. Treat. 2010, 122:35-43.
64. Correia A.L., Bissell M.J. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat. 2012, 15:39-49.
65. Boyd N.F., Li Q., Melnichouk O., Huszti E., Martin L.J., Gunasekara A., et al. Evidence that breast tissue stiffness is associated with risk of breast cancer. PLoS ONE 2014, 9:e100937.
66. Kharaishvili G., Simkova D., Bouchalova K., Gachechiladze M., Narsia N., Bouchal J. The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell Int. 2014, 14:41.
67. Samani A., Zubovits J., Plewes D. Elastic moduli of normal and pathological human breast tissues: an inversion-technique-based investigation of 169 samples. Phys. Med. Biol. 2007, 52:1565-1576.
68. Butcher D.T., Alliston T., Weaver V.M. A tense situation: forcing tumour progression. Nat. Rev. Cancer 2009, 9:108-122.
69. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
70. Kass L., Erler J.T., Dembo M., Weaver V.M. Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. Int. J. Biochem. Cell Biol. 2007, 39:1987-1994.
71. Faurobert E., Bouin A.P., biges-Rizo C. Microenvironment, tumor cell plasticity, and cancer. Curr. Opin. Oncol. 2015, 27:64-70.
72. Provenzano P.P., Inman D.R., Eliceiri K.W., Knittel J.G., Yan L., Rueden C.T., et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008, 6:11. 10.1186/1741-7015-6-11.:11-6.
73. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
74. Provenzano P.P., Inman D.R., Eliceiri K.W., Keely P.J. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene 2009, 28:4326-4343.
75. Mouw J.K., Yui Y., Damiano L., Bainer R.O., Lakins J.N., Acerbi I., et al. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat. Med. 2014, 20:360-367.
76. Wei S.C., Fattet L., Tsai J.H., Guo Y., Pai V.H., Majeski H.E., et al. Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nat. Cell Biol. 2015, %20. 10.1038/ncb3157.:10.
77. Nguyen T.V., Sleiman M., Moriarty T., Herrick W.G., Peyton S.R. Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening. Biomaterials 2014, 35:5749-5759.
78. Zustiak S., Nossal R., Sackett D.L. Multiwell stiffness assay for the study of cell responsiveness to cytotoxic drugs. Biotechnol. Bioeng. 2014, 111:396-403.
79. Hayashi M., Yamamoto Y., Ibusuki M., Fujiwara S., Yamamoto S., Tomita S., et al. Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. Ann. Surg. Oncol. 2012, 19:3042-3049.
80. Evans A., Armstrong S., Whelehan P., Thomson K., Rauchhaus P., Purdie C., et al. Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer?. Br. J. Cancer 2013, 109:2798-2802.
81. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000, 60:2497-2503.
82. Jacobetz M.A., Chan D.S., Neesse A., Bapiro T.E., Cook N., Frese K.K., et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013, 62:112-120.
83. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
84. Falou O., Sadeghi-Naini A., Prematilake S., Sofroni E., Papanicolau N., Iradji S., et al. Evaluation of neoadjuvant chemotherapy response in women with locally advanced breast cancer using ultrasound elastography. Transl. Oncol. 2013, 6:17-24.
85. Chaudhuri O., Koshy S.T., Branco da C.C., Shin J.W., Verbeke C.S., Allison K.H., et al. Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium. Nat. Mater. 2014, 13:970-978.